A Prospective Trial of Revlimid in Transfusion Dependent Patients With Non-del (5q) Low/Intermediate-1 Risk Myelodysplastic Syndrome.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2016 ).
- 15 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.
- 15 Jan 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.